CoPlavix

CoPlavix Dosage/Direction for Use

Manufacturer:

Sanofi

Distributor:

DCH Auriga - Healthcare
/
Four Star
Full Prescribing Info
Dosage/Direction for Use
Posology: Adults and elderly: CoPlavix should be given as a single daily 75 mg/100 mg dose.
CoPlavix is used following initiation of therapy with clopidogrel and ASA given separately.
In patients with non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): The optimal duration of treatment has not been formally established. Clinical trial data support use up to 12 months, and the maximum benefit was seen at 3 months (see Pharmacology: Pharmacodynamics under Actions). If the use of CoPlavix is discontinued, patients may benefit with continuation of one antiplatelet medicinal product.
In patients with ST segment elevation acute myocardial infarction: Therapy should be started as early as possible after symptoms start and continued for at least four weeks. The benefit of the combination of clopidogrel with ASA beyond four weeks has not been studied in this setting (see Pharmacology: Pharmacodynamics under Actions). If the use of CoPlavix is discontinued, patients may benefit with continuation of one antiplatelet medicinal product.
If a dose is missed: Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time.
For more than 12 hours: patients should take the next dose at the regular scheduled time and should not double the dose.
Paediatric population: The safety and efficacy of CoPlavix in children and adolescents under 18 years old have not been established. CoPlavix is not recommended in this population.
Renal impairment: CoPlavix must not be used in patients with severe renal impairment (see Contraindications). Therapeutic experience is limited in patients with mild to moderate renal impairment (see Precautions). Therefore CoPlavix should be used with caution in these patients.
Hepatic impairment: CoPlavix must not be used in patients with severe hepatic impairment (see Contraindications). Therapeutic experience is limited in patients with moderate hepatic disease who may have bleeding diatheses (see Precautions). Therefore CoPlavix should be used with caution in these patients.
Method of administration: For oral use.
It may be given with or without food.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in